These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28482067)

  • 21. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
    Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
    Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Characteristics and Magnetic Resonance Imaging-Based Prediction of the KLF4
    von Spreckelsen N; Waldt N; Timmer M; Goertz L; Reinecke D; Laukamp K; Pennig L; Grau S; Deckert M; Kirches E; Stavrinou P; Mawrin C; Goldbrunner R
    World Neurosurg; 2021 Oct; 154():e665-e670. PubMed ID: 34343686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AKT1
    John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
    Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
    Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
    Johnson MD; O'Connell MJ; Walter K
    BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
    Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
    Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
    Brastianos PK; Horowitz PM; Santagata S; Jones RT; McKenna A; Getz G; Ligon KL; Palescandolo E; Van Hummelen P; Ducar MD; Raza A; Sunkavalli A; Macconaill LE; Stemmer-Rachamimov AO; Louis DN; Hahn WC; Dunn IF; Beroukhim R
    Nat Genet; 2013 Mar; 45(3):285-9. PubMed ID: 23334667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NF2 status of meningiomas is associated with tumour localization and histology.
    Kros J; de Greve K; van Tilborg A; Hop W; Pieterman H; Avezaat C; Lekanne Dit Deprez R; Zwarthoff E
    J Pathol; 2001 Jul; 194(3):367-72. PubMed ID: 11439370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High p-mTOR expression is associated with recurrence and shorter disease-free survival in atypical meningiomas.
    Barresi V; Lionti S; La Rocca L; Caliri S; Caffo M
    Neuropathology; 2019 Feb; 39(1):22-29. PubMed ID: 30511495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. POLR2A Mutation is a Poor Prognostic Marker of Cerebellopontine Angle Meningioma.
    Okano A; Miyawaki S; Teranishi Y; Hongo H; Dofuku S; Ohara K; Sakai Y; Shin M; Nakatomi H; Saito N
    Neurosurgery; 2024 Aug; 95(2):275-283. PubMed ID: 38380947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological and molecular characteristics of pediatric meningiomas.
    Battu S; Kumar A; Pathak P; Purkait S; Dhawan L; Sharma MC; Suri A; Singh M; Sarkar C; Suri V
    Neuropathology; 2018 Feb; 38(1):22-33. PubMed ID: 28901666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges.
    Fountain DM; Smith MJ; O'Leary C; Pathmanaban ON; Roncaroli F; Bobola N; King AT; Evans DG
    Oncogene; 2021 Feb; 40(5):875-884. PubMed ID: 33262459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis.
    Keppler-Noreuil KM; Baker EH; Sapp JC; Lindhurst MJ; Biesecker LG
    Am J Med Genet A; 2016 Oct; 170(10):2605-10. PubMed ID: 27550858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
    Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
    Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of
    Malgulwar PB; Kakkar A; Sharma MC; Ghosh R; Pathak P; Sarkar C; Suri V; Singh M; Kale SS; Faruq M
    Neurol India; 2019; 67(6):1492-1497. PubMed ID: 31857543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-grade meningiomas: biology and implications.
    Bi WL; Prabhu VC; Dunn IF
    Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
    Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
    J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.